Core Viewpoint - UTime Limited will implement a reverse share split of its Class A ordinary shares at a ratio of 1-for-10, effective on or around March 31, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2][4]. Group 1: Reverse Share Split Details - The reverse share split will adjust the par value of the Ordinary Shares from $0.0001 to $0.001 per share and will continue trading under the symbol "WTO" on Nasdaq [2]. - The number of issued and outstanding shares will decrease from approximately 36 million to approximately 3.6 million [4]. - No fractional shares will be issued; fractional interests will be rounded up to the nearest whole number [3]. Group 2: Shareholder Information - VStock Transfer, LLC is designated as the exchange agent and will provide instructions to shareholders regarding the exchange of pre-reverse share split share certificates [5][6]. - Shareholders holding shares in book-entry form or brokerage accounts do not need to take any action for the reverse share split [5]. Group 3: Company Overview - UTime Ltd., established in 2008, focuses on providing cost-effective mobile devices globally, particularly aiding low-income individuals in both established and emerging markets [7]. - The company has expanded its product line to include smart electric vehicle chargers in response to global energy conservation demands [7].

Core Viewpoint - UTime Limited has received a notification from Nasdaq regarding non-compliance with minimum bid price requirements, as its share price has been below $1.00 for 30 consecutive business days [1][2]. Group 1: Company Compliance Status - The notification does not have an immediate effect on UTime's listing on Nasdaq [2]. - UTime has until April 8, 2025, to regain compliance with the minimum bid price requirement [2]. - If UTime's share price reaches at least $1 for 10 consecutive business days during the 180-day period, Nasdaq will confirm compliance [2]. Group 2: Potential Remedies - If UTime does not regain compliance within the initial 180-day period, it may be eligible for an additional 180 days, provided it meets other listing requirements [2]. - The company may consider a reverse stock split as a potential remedy to address the bid price deficiency [2]. Group 3: Company Overview - UTime Ltd. was established in 2008 and focuses on providing cost-effective mobile devices globally, particularly to low-income individuals in both established and emerging markets [3]. - The company has expanded its product line to include smart electric vehicle chargers in response to global energy conservation demands [3].

Core Viewpoint - UTime Limited has announced a registered direct offering to sell $5 million of its ordinary shares, aiming to enhance its capital for further business operations and product development [1][2]. Group 1: Offering Details - UTime will sell 7,692,308 ordinary shares at a price of $0.65 per share, with gross proceeds estimated at $5 million before expenses [1]. - The offering is expected to close around September 16, 2024, pending customary closing conditions [1]. Group 2: Regulatory Information - The shares are being offered under a shelf registration statement on Form F-3, initially filed with the SEC on April 24, 2024, and declared effective on June 10, 2024 [2]. - A prospectus supplement detailing the terms of the offering will be filed with the SEC [2]. Group 3: Company Overview - UTime Ltd., established in 2008, focuses on providing cost-effective mobile devices globally, particularly targeting low-income individuals in both established and emerging markets [4]. - The company has expanded its product line to include smart electric vehicle chargers in response to global energy conservation demands [4].

Company Overview - UTime Limited is a mobile device manufacturing company focused on providing cost-effective products and solutions to consumers globally, particularly targeting low-income individuals in both established and emerging markets [5] - The company has expanded its product line to include smart electric vehicle chargers in response to global energy conservation and carbon reduction demands since July 2023 [5] Reverse Share Split Announcement - UTime announced a reverse share split of its outstanding ordinary shares at a ratio of 1-for-25, effective on or around September 11, 2024 [1][2] - The reverse share split aims to help the company regain compliance with Nasdaq's minimum bid price requirement of $1.00 per ordinary share for continued listing [2] - Following the reverse share split, the number of issued and outstanding shares will decrease from approximately 450 million to about 18 million [3] Shareholder Information - No fractional shares will be issued; all fractional interests will be rounded up to the nearest whole number of ordinary shares [3] - VStock Transfer, LLC is designated as the exchange agent and paying agent for the reverse share split, and shareholders in book-entry form or brokerage accounts need not take any action [4]

Core Viewpoint - UTime Ltd is addressing recent unusual share price volatility and is committed to transparency and regulatory compliance while continuing its operations normally and entering the medical industry [2][3]. Group 1: Company Operations and Developments - The company has entered the medical industry, collaborating with Dr. Ehud Baron and trial organizations, and plans to acquire a laboratory for developing a monkeypox vaccine [2]. - UTime is focused on transforming health and wellness through innovative medical wearable technologies, aiming to provide effective solutions for disease prevention and health management globally [5]. Group 2: Market Communication and Investor Relations - The company is conducting an internal investigation to determine any potential undisclosed information leaks affecting share price and may engage legal counsel for a short-selling investigation [3]. - UTime urges investors to remain rational and not be influenced by short-term market sentiment, promising to communicate any new developments through official channels [4].

Core Insights - UTime Limited has initiated comprehensive financial and legal due diligence on Bowen Therapeutics Inc, aiming to acquire the company to enhance its position in the innovative medical products sector [1][2][3] Company Overview - UTime Limited, established in 2008, focuses on providing cost-effective mobile devices globally and has recently shifted its commitment towards health and wellness through innovative medical wearable technologies since 2024 [5] Acquisition Strategy - The acquisition of Bowen Therapeutics is a strategic move for UTime, leveraging Bowen's strong reputation and unique R&D capabilities, particularly in the development of a monkeypox vaccine, to facilitate technological innovation and market expansion [2][3] Due Diligence Process - The due diligence process will encompass a thorough examination of Bowen Therapeutics's financial statements, assets, liabilities, cash flow, tax records, accounting systems, corporate governance, contracts, intellectual property rights, and any pending litigation [3][4] - This process is essential for UTime to assess potential risks and opportunities, ensuring informed decision-making aligned with the company's long-term growth strategy [4]

Core Insights - UTime Limited has announced a collaboration on Circul VS, a continuous blood pressure measurement technology system aimed at improving cardiovascular and cerebrovascular health management [1][2] - The Circul VS system includes BPwatch, Ring, and Smart Cradle, designed to monitor rapid blood pressure fluctuations, which are often overlooked by competitors [1][2] - The technology utilizes advanced ultrasound sensing and intelligent algorithms to provide real-time blood pressure waveform data with high accuracy, comparable to invasive methods [2][3] Company Overview - UTime Limited, established in 2008, focuses on providing cost-effective mobile devices and has recently shifted towards innovative medical wearable technologies for health and wellness [4] - The company aims to enhance global health management through strategic partnerships and cutting-edge research, targeting both established and emerging markets [4] Product Development - Circul VS has been developed for various clinical applications, including hypertension screening, long-term management of diagnosed patients, and acute monitoring in hospitals [3] - The system has undergone clinical trials in multiple hospitals, receiving positive feedback for its performance in non-invasive monitoring [2][3] - UTime plans to continue refining Circul VS to improve its intelligence and accuracy for broader use in medical settings, particularly in ICUs [3]

Core Viewpoint - UTime Limited is actively participating in international medical fairs and conferences to showcase its innovations in medical devices and solutions, aiming to enhance its global presence and partnerships in the healthcare industry [1][2]. Group 1: Upcoming Events - UTime will exhibit at MEDICA in Düsseldorf, Germany, focusing on medical monitoring devices and smart diagnostic tools, highlighting its innovations across the medical technology value chain [1]. - The company plans to attend several conferences in the United States, including the Cardiology Society Conference, Sleep Conference, and Hypertension Conference, providing a platform to present technological advancements and gain insights from industry experts [2]. Group 2: Commitment to Innovation - UTime's participation in these events reflects its commitment to influencing the global medical landscape and enhancing human health through technological innovation [2]. - The company aims to explore collaborative projects with international healthcare organizations and research institutes, particularly in telemedicine and artificial intelligence applications in healthcare, to accelerate the rollout of its products [3]. Group 3: Company Overview - UTime is dedicated to transforming health and wellness through innovative medical wearable technologies, leveraging research and strategic partnerships to provide effective solutions for disease prevention and health management globally [4].

Core Insights - UTime Limited is advancing its strategy in AI-driven health solutions, focusing on smart medical wearable products [1][2] - The company is collaborating with Dr. Ehud Baron to enhance its blood pressure measurement offerings and expand into hemodynamic and health mapping products [1] - UTime plans to launch additional products for monitoring key health indicators, including heart rate and sleep [2] Company Overview - UTime Limited, established in 2008, aims to provide cost-effective mobile devices globally, particularly for low-income individuals [3] - Since 2024, the company has been dedicated to transforming health and wellness through innovative medical wearable technologies [3] - UTime seeks to leverage research and strategic partnerships to offer effective solutions for disease prevention and health management [3]

Executive Compensation - The company reported an aggregate compensation of RMB 0.7 million (approximately $0.1 million) to executive officers for the fiscal year ended March 31, 2024[296]. - No cash compensation was paid to non-executive directors during the same fiscal year[296]. - The company has not granted any equity awards to directors or executive officers for the fiscal year ended March 31, 2024[296]. - The company has not set aside or accrued any amounts for pension or retirement benefits for directors and executive officers[296]. - The annual cash compensation for independent directors ranges from $100,000 to $120,000, with the possibility of equity payments[299]. - The cash compensation for newly appointed directors is approximately $435.60 (RMB 3,000) per year, paid quarterly[300]. - The company may terminate executive officers' employment without cause with 30 days' notice, providing severance payments not exceeding twelve months of base salary[110]. - The directors are not entitled to receive any remuneration upon termination of employment[302]. - The company has established a Compensation Committee to oversee executive compensation, ensuring compliance with independence standards[305]. Board Diversity - The board of directors consists of 5 members, with 1 female and 4 male directors[297]. - The company has a diverse board with no underrepresented individuals in the home country jurisdiction[297]. Financial Reporting and Asset Management - The company follows the allowance method for uncollectible accounts receivable, regularly assessing collectability based on historical experience and economic conditions[290]. - Inventory is stated at the lower of cost or net realizable value, with periodic assessments for impairment based on product life-cycle[292]. - The company reviews the carrying value of long-lived assets and recognizes impairment losses when anticipated cash flows are less than carrying value[292]. Share Issuance and Ownership - The company has registered an aggregate of 58,817,092 ordinary shares for issuance under the 2024 Performance Incentive Plan[308]. - As of July 29, 2024, there are 450,930,953 ordinary shares issued and outstanding, with directors and executive officers collectively owning 4,380,000 shares, representing 0.97%[305]. - The company has not issued any shares under the 2024 Performance Incentive Plan as of the date of the report[308]. Risk Management - The company faces foreign exchange risks due to international operations, particularly with revenue and expenses in U.S. dollars and Renminbi[310]. - The company has not been exposed to material risks due to changes in interest rates[394]. - Interest income is primarily generated from excess cash held in interest-bearing bank deposits[394]. - The company has not used any derivative financial instruments to manage interest rate risk exposure[394]. - Investments in fixed rate and floating rate interest-earning instruments carry a degree of interest rate risk[394]. - Fixed rate securities may have their fair market value adversely impacted by rising interest rates[394]. - Floating rate securities may produce less income than expected if interest rates fall[394]. - There are no applicable debt securities, warrants, rights, or other securities reported[395]. Audit and Compliance - The Audit Committee consists of three independent directors, with Na Cai serving as the chairman, ensuring compliance with Nasdaq listing rules[303].